This website uses cookies, including third party ones, to allow for analysis of how people use our website in order to improve your experience and our services. By continuing to use our website, you agree to the use of such cookies. Click here for more information on our and .
Healthcare
Antidyslipidemics | End of an Era
[tweetmeme source= "informa_oz" only_single=false] The domination of the antidyslipidemic market by five top brands is set to fundamentally change over the next 10 years as novel agents fail to meet the success of their predecessors, claims a new report from independent market analyst, Datamonitor. The top five antidyslipidemic brands: Lipitor (atorvastatin, Pfizer), Crestor (rosuvastatin, AstraZeneca),…
28 Sep 2010, by Informa InsightsHealthcare
Cancer Targeted Therapies and Immunotherapies | Resisting Competitive Pressures
[tweetmeme source= "informa_oz" only_single=false] Drug developers aiming to emulate the success of cancer targeted therapies and immunotherapy brands will struggle as a result of heightened competition and pharmacoeconomic constraints, suggests independent market analyst, Datamonitor. Over the last decade the targeted therapies and immunotherapies class has fuelled growth in the oncology market, making it very attractive…
28 Sep 2010, by Informa InsightsHealthcare
J&J in Talks to Buy Crucell | Expert Analyst Comment
[tweetmeme source= "informa_oz" only_single=false] Johnson & Johnson is in advanced negotiations to buy Dutch biotechnology company Crucell NV for €1.75 billion ($2.29 billion), the two companies said today. Giles Somers, senior healthcare analyst at Datamonitor comments: “So, one more big Pharma enters the vaccines space – following the example of Pfizer (through the acquisition of…
28 Sep 2010, by Informa InsightsHealthcare
Multi-blockbuster sales expected as Gilenya changes Multiple Sclerosis landscape
[tweetmeme source= "informa_oz" only_single=false] Melbourne, 23rd September 2010 - Gilenya is set to become the leading treatment in multiple sclerosis (MS) with multi-blockbuster sales, ending the decade long dominance of interferon betas and Copaxone (glatiramer acetate, Teva) says Trung Huynh, healthcare analyst at Datamonitor. “The FDA approved Novartis’s Gilenya (formally Gilenia; fingolimod) yesterday. It is…
28 Sep 2010, by Informa InsightsEducation | Healthcare
new subgroups on Linkedin!
[tweetmeme source= "informa_oz" only_single=false] Exciting news everyone! We're slowly reorganising our groups and subgroups in Linkedin and will be updating the blog to keep YOU update on the latest subgroups created so that you can connect with the industry/sector that you want to! We've created 2 new subgroups under the Informa Healthcare Community parent group.…
22 Sep 2010, by Informa InsightsHealthcare
Australian Obesity Summit Exclusive Interviews
[tweetmeme source= "informa_oz" only_single=false] We had the opportunity to speak to Professor Boyd Swinburn, Population Health, and Director of WHO Collaboration Centre for Obesity Prevention, Deakin University, about fighting the pressure for the over consumption of poor foods. [youtube=http://www.youtube.com/watch?v=LpE3FCs5jac] **************** Watch Sharif Deen, Personal Trainer of Sharifit and Former Contestant of The Biggest Loser, as…
7 Sep 2010, by Informa InsightsHealthcare
Exclusive interviews from Health Congress 2010
[tweetmeme source= "informa_oz" only_single=false] We had the opportunity to interview Dr Clive Wright, Chief Dental Officer, NSW Health about the impact of dental disease on general health and wellbeing and if there is a need for a universal scheme for access to dental care. [youtube=http://www.youtube.com/watch?v=gsFegdT0eV8] ***************** We had the opportunity to speak to David Crosbie,…
7 Sep 2010, by Informa InsightsHealthcare
12th Annual Health Congress 2010
[youtube=http://www.youtube.com/watch?v=TLGERWVpe4o] Healthcare reform is high on the Rudd government’s policy agenda. In a highly anticipated announcement last March, Prime Minister Rudd made a promise to revamp the national hospital and healthcare system. It was during this announcement that Informa held its 12th Annual Health Congress on the 3rd, 4th and 5th of March in Sydney.…
27 Apr 2010, by Informa InsightsHealthcare
Interview with Professor Warwick Anderson of NHMRC
[youtube=http://www.youtube.com/watch?v=kNoga0_Nskw] Professor Warwick Anderson AM, CEO, National Health and Medical Research Council, spoke to us about the main health issues today. He discusses the future health challenges of an ageing population, health inequalities in indigenous populations and the research activities of the NHMRC to deal with these complex issues. Website: http://www.healthcongress.com.au Contact: +61 2 9080…
19 Feb 2010, by Informa InsightsHealthcare
Convergence of health insurance companies to continue, says expert
MARK FITZGIBBON, CEO of nib health funds The merging of companies in the health insurance industry will continue, but its pace will be dependent on both economic factors and the appetite of companies for change, according to Mark Fitzgibbon, Chief Executive Officer of nib health funds. Mr Fitzgibbon will be addressing the CEO Roundtable Discussion…
18 Jun 2009, by Informa InsightsInforma Connect Australia is the nation's leading event organiser. Our events comprise of large scale exhibitions, industry conferences and highly specialised corporate training.
